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Background. Letermovir is a novel cytomegalovirus antiviral that is approved for prophylaxis in hematopoietic stem cell trans-
plantation recipients
Methods.  After obtaining informed consent, letermovir prophylaxis was started in a patient with a presumed late-onset pri-
mary, combined T- and B-cell immunodeficiency. Plasma CMV DNAemia was monitored with real-time polymerase chain reaction, 
and letermovir resistance analyses were performed using Sanger sequencing and Illumina MiSeq next-generation sequencing.
Results. A letermovir-resistant cytomegalovirus variant (C325Y mutation in UL56) emerged 17 weeks after start of prophylaxis. 
The letermovir-resistant variant was able to reactivate without drug selective pressure as this variant was again detected in plasma 
20.6 weeks after stopping of letermovir.
Conclusions. This case indicates that the C325Y mutation in UL56 does not significantly alter fitness of cytomegalovirus in vivo.
Keywords.  letermovir; resistance; viral fitness.
Human cytomegalovirus (CMV) causes significant compli-
cations in immunocompromised patients, which can be pre-
vented and treated with the antiviral drugs (val)ganciclovir, 
foscarnet, and cidofovir. However, treatment is often compli-
cated by drug toxicity, antiviral resistance, and the need for in-
travenous (i.v.) drug administration [1, 2]. Letermovir, a novel 
CMV antiviral that was recently approved by the US Food and 
Drug Administration (FDA) and European Medicines Agency 
(EMA) for prophylactic use in hematopoietic stem cell trans-
plantation (HSCT) recipients, has several advantages over cur-
rently used CMV antivirals. Letermovir can be administrated 
either orally or intravenously and shows mild toxicity. In addi-
tion, there is no risk of cross-resistance with existing anti-CMV 
drugs due to a different mechanism of action [1, 3].
METHODS
After obtaining informed consent, letermovir prophylaxis 
was started in a patient with a presumed late-onset primary, 
combined T- and B-cell immunodeficiency. Plasma CMV-
DNAemia was monitored by an internally controlled, in-house 
developed, dual target (UL54 and UL75), real-time polymerase 
chain reaction (PCR) using the 1st WHO International Standard 
for Human Cytomegalovirus for Nucleic Acid Amplification 
Techniques (code: 09/162, National Institute for Biological 
Standards and Control, Hertfordshire, Great Britain) as quan-
tification standard. Cytomegalovirus-specific T-cell responses 
were analyzed with CMV ELISPOT (Oxford Immunotec Ltd., 
Abingdon, Great Britain) and CMV-QuantiFERON (QIAGEN 
GmbH, Hilden, Germany). Letermovir resistance analysis 
was performed by genotypic analysis of UL56 using Sanger 
sequencing and Illumina MiSeq (amplicon sequencing). Part 
of UL56 was amplified resulting in a PCR product, 1300-bp of 
which comprises the amino acids 231–369 described to be rel-
evant for letermovir drug resistance. Amplification sensitivity 
was reached by performing a nested PCR including a first PCR 
with 25 cycles and a second PCR with 35 cycles. Ganciclovir, 
foscarnet, and cidofovir resistance analysis were performed by 
genotypic analysis of UL54 and UL97 using Sanger sequencing. 
All analyses were performed in ISO15189:2012 (or equivalent) 
accredited settings.
RESULTS
A 52-year-old female was referred to the Erasmus Medcial 
Center for analysis of a presumed primary immunodeficiency, 
after experiencing a recent episode of CMV colitis and CMV 
retinitis. Immunological analyses showed a combined B- and 
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T-cell deficiency with total T-cell numbers of 200 cells/µL 
(lower reference value [LRV], 700 cells/µL), CD4+ T cells of 
40 cells/µL (LRV, 300 cells/µL), CD8+ T cells of 140 cells/µL 
(LRV, 200 cells/µL), total B cells of 70 cells/µL (LRV, 100 cells/
µL), and a severe hypogammaglobulinemia (immunoglobulin 
[Ig]G 1.5 g/L [LRV, 7.0 g/L], IgA 0.28 g/L [LRV, 0.76 g/L], IgM 
0.21 g/L [LRV, 0.45 g/L]). She was extensively evaluated for a 
secondary immunodeficiency, including bone marrow aspira-
tion and total-body positron emission tomography/computed 
tomography scan, which not revealed an underlying (hemato-
logical) malignancy. She tested negative for human immunode-
ficiency virus (HIV). Gene panel testing comprising over 350 
primary immunodeficiency-associated genes was performed 
using whole exome sequencing [4]. No known pathogenic mu-
tations were found. Because no secondary cause of the immu-
nodeficiency was found, a late-onset primary, combined T- and 
B-cell immunodeficiency was assumed, and she was started on 
monthly i.v. Ig replacement therapy and 480 mg of co-trimoxa-
zole prophylaxis once daily.
Within the next 2 years, the patient required antiviral therapy 
for multiple episodes of CMV end-organ disease and CMV re-
activations. Because the CMV colitis and CMV retinitis relapse 
was unresponsive to ganciclovir, a switch to foscarnet was re-
quired. Genotypic resistance analyses of plasma and colonic 
biopsies showed the M460I mutation in UL97, which confers 
a 4-fold reduced susceptibility to ganciclovir [5]. During the 
next 18 months, the patient received a total of 10 months i.v. 
foscarnet for relapses of CMV colitis and retinitis and as pre-
emptive therapy (Figure 1). To stimulate her T cells, interferon 
alpha-2a therapy was started, but it was halted after 3 months 
because of inefficacy. Cytomegalovirus Igs were combined with 
foscarnet to treat relapses of CMV end-organ disease. After these 
18 months, no specific T-cell responses against CMV were de-
tected (not reactive CMV-ELISPOT and CMV-QuantiFERON), 
indicating a persisting high risk for severe active CMV infec-
tions. Foscarnet i.v. treatments required hospitalization and 
were complicated by anemia, leukopenia, hypomagnesemia, and 
renal impairment. Therefore, we explored other treatment op-
tions. Cidofovir has considerable renal toxicity and cidofovir re-
sistance mutations and can confer cross-resistance to foscarnet. 
Maribavir and brincidofovir are not approved by the FDA or 
EMA yet. Letermovir is FDA and EMA approved, has a mild tox-
icity profile, and does not confer cross-resistance to other CMV 
antivirals. Therefore, after obtaining informed consent, the pa-
tient was switched to off-label letermovir prophylaxis (480 mg 
orally once daily) as soon as plasma CMV DNAemia was <50 
IU/mL (limit of quantification). During letermovir prophylaxis, 
several breakthroughs of CMV replication occurred (Figure 1). 
The patient did not experience CMV end-organ disease during 
or after letermovir prophylaxis failure. The first breakthrough 
coincided with an episode of vomiting and may have resulted 
in poor letermovir uptake. No causes could be identified for 
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Figure 1. Course of plasma cytomegalovirus (CMV) DNAemia during treatment with intravenous foscarnet (black bars) and oral letermovir (gray bar). Dotted horizontal line 
at 1.7 log10 is the lower limit of quantification (50 IU/mL). Boxes with gray arrows show the results from genotypic resistance analyses.
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the other breakthroughs. Letermovir was continued, because 
plasma CMV DNAemia rapidly returned <50 IU/mL. However, 
11.3 weeks after letermovir start, CMV breakthrough persisted 
and plasma CMV DNAemia increased to 3730 IU/mL at week 
17 and 6580 IU/mL at week 17.4. Genotypic resistance analysis 
(Sanger sequencing) showed the C325Y mutation in UL56 in 
the sample obtained at week 17, which confers high-level re-
sistance to letermovir [6, 7]. Resistance mutations against (val)
ganciclovir, foscarnet, or cidofovir were not detected in this 
sample (Sanger sequencing of UL54 and UL97). The letermovir 
resistance mutation was confirmed with next-generation 
sequencing (NGS) (MiSeq; Illumina) showing the UL56 C325Y 
mutation at a frequency of 99.7%. The C325Y mutation was not 
detected by NGS (below cutoff of 1%) or Sanger sequencing in 
a sample obtained 2.5 months before start of letermovir, clearly 
indicating that the C325Y mutation was selected for during 
prophylaxis with letermovir. Letermovir was stopped and re-
placed with foscarnet. Ten days after start of foscarnet, the 
UL56 C325Y mutation was still detected at a frequency of 99.6% 
(NGS). Foscarnet was continued and plasma CMV DNAemia 
returned to <50 IU/mL. During the next 4 weeks, the patient 
did not receive any CMV antivirals. Plasma CMV DNAemia 
rose again to 2010 IU/mL, and no drug resistance mutations 
were detected in UL56 (Sanger, NGS), UL54 (Sanger), and UL97 
(Sanger). Three days later foscarnet i.v. was restarted, and an-
other 4 days later CMV load declined to 740 IU/mL. We were 
surprised to find that the C325Y mutation in UL56 was detected 
in this sample (Sanger, NGS 99.4% frequency), whereas no re-
sistance mutations were detected in UL54 and UL97 (Sanger). 
Plasma CMV DNAemia declined to below 50 IU/mL. One 
month after stopping foscarnet, plasma CMV DNAemia rose 
to 1740 IU/mL and the C325Y mutation in UL56 was again 
detected by Sanger sequencing. Foscarnet was reinitiated and 
plasma CMV DNAemia declined to <50 IU/mL.
DISCUSSION
This is the first report on the off-label use of letermovir in a 
patient with presumed primary, combined immunodeficiency. 
Letermovir was well tolerated, but several breakthroughs of 
CMV replication occurred, with emerging antiviral resistance. 
Our patient was treated with a dose of 480 mg per day, which 
has proven to be safe and effective as CMV prophylaxis among 
HSCT recipients in a phase 3 clinical trial [3]. Nevertheless, 
7.7% of the participants experienced a breakthrough of CMV 
replication during prophylaxis. Higher dosages could be more 
effective in preventing these breakthroughs, but data on this 
topic are sparse. The registration label reports healthy subjects 
receiving letermovir dosages ranging from 720 mg per day up to 
1440 mg per day for up to 14 days with similar adverse events as 
the 480 mg per day dosage [8]. Turner et al [9] reported the use 
of higher dosages for off-label treatment of 4 transplant patients 
with CMV retinitis (720 and 960  mg per day), but resistance 
emerged in 2. It should be noted that there is a lack of safety data 
on sustained high doses of letermovir (>480 mg per day) in pub-
lished literature. Currently, there is an urgent need for additional 
data on dosage and effectiveness in different patient groups.
There are an increasing number of reports of acquired 
letermovir resistance. Among HSCT recipients, UL56 mutations 
V236M [1, 3], C325W [3], C325F [10], and C325Y [11, 12] are 
reported; in solid organ transplants patients, the C325Y [9, 13] 
and C325F [9] are reported. In this case, the UL56 mutation 
C325Y emerged after 17 weeks of letermovir prophylaxis. Taken 
together, these data indicate that UL56 mutation at position C325 
is the main acquired letermovir resistance mutation in vivo. We 
recommend tight monitoring of CMV DNAemia during pro-
phylaxis with letermovir because timely resistance might occur. 
Only a single transition can result in the C325Y mutation re-
ducing susceptibility by >3000-fold with minimal impact on viral 
replication in vitro [6, 7]. Our results indicate that CMV strains 
harboring the C325Y mutation in UL56 are able to reactivate in 
humans without selective drug pressure because the C325Y mu-
tation was still detected in plasma during the second episode of 
CMV reactivation occurring 20.6 weeks after stopping letermovir. 
It is interesting to note that during the first episode of CMV reac-
tivation, the UL56 C325Y mutation was not detected (9.6 weeks 
after stopping letermovir), although 1 week later the mutation 
was detected. In between these 2 samples, foscarnet was started. 
Although we cannot rule out a decreased foscarnet susceptibility 
for the variant harboring the UL56 C325Y mutation, it seems 
unlikely as previous in vitro studies showed no cross-resistance 
between letermovir and foscarnet, no foscarnet mutations were 
detected in this particular variant and the patient responded well 
to foscarnet treatment. We hypothesize that during this episode 
multiple CMV variants were reactivating and that the letermovir-
resistant variant was the majority in the second sample.
CONCLUSIONS
Regardless of the apparent low barrier to resistance, letermovir 
can positively contribute to management of CMV infections. 
First, letermovir has a favorable safety profile compared with 
other CMV antivirals and is not associated with myelotoxicity 
and nephrotoxicity. Second, letermovir can be used orally so no 
hospitalization is needed nor an i.v. access. Finally, letermovir 
targets the CMV terminase complex instead of CMV deoxyribo-
nucleic acid polymerase so no cross-resistance with the other ap-
proved CMV antivirals occurs [3], suggesting discussions about 
administration of combination therapies or cycling of therapies. 
However, it should be noted that without immune control, any 
antiviral therapy of CMV will eventually fail and acquired an-
tiviral drug resistance will emerge [14]. More data are needed 
to provide insight of in vivo-detected mutations, interpretation 
of genotyping results, and the clinical relevance of the results. 
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This can all be provided by a CMV registry. Moreover, gener-
ated knowledge can contribute to CMV consensus guidelines 
and treatment algorithms. Databases established as resistance 
surveillance and resistance interpretation for HIV and hepatitis 
C virus are successful and provide useful information. A similar 
approach for CMV would be highly recommended.
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